BiotechTube

mRNA-1195.1

Phase 1Active
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epstein-Barr Virus Infection

Conditions

Epstein-Barr Virus Infection

Trial Timeline

Apr 5, 2023 → Oct 7, 2026

NCT ID
NCT05831111

About mRNA-1195.1

mRNA-1195.1 is a phase 1 stage product being developed by Moderna for Epstein-Barr Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT05831111. Target conditions include Epstein-Barr Virus Infection.

Clinical Trials (1)

NCT IDPhaseStatus
NCT05831111Phase 1Active

Competing Products

5 competing products in Epstein-Barr Virus Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1189ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
17
Durvalumab + EpacadostatAstraZenecaPhase 2
27
tabelecleucelAtara BiotherapeuticsPre-clinical
16